ADALIMUMAB (HUMIRA®) INHIBITS RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH LONG-STANDING DISEASE: DATA AT TWO YEARS

被引：0
|
作者：
Keystone, E. [1 ]
Kavanaugh, A. [2 ]
Sharp, J. [3 ]
Spencer-Green, G. [4 ]
Segurado, O. G. [5 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Calif San Diego, Ctr Innovat Therapy, San Diego, CA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Abbott Labs, Parsippany, NJ USA
[5] Abbott Labs, Chicago, IL USA
来源：
RHEUMATOLOGY | 2004年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [1] Adalimumab inhibits radiographic disease progression in long-standing, rapidly progressive rheumatoid arthritis
    Rau, R
    Herborn, G
    de Putte, LBV
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 191 - 191
  • [2] Inhibition of radiographic disease progression in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA®) plus methotrexate
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, GT
    Perez, JL
    Sasso, EH
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 419 - 419
  • [3] Sustained radiographic inhibition with adalimumab (HUMIRA™) over 2 years in patients with long standing rheumatoid arthritis (RA).
    Keystone, EC
    Kavanaugh, A
    Sharp, JT
    Spencer-Green, GT
    Fischkoff, SA
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S315 - S315
  • [4] Inhibition of radiographic progression in patients with long-standing rheumatoid arthritis treated with adalimumab plus methotrexate for 5 years
    Keystone, E. C.
    Kavanaugh, A. F.
    Sharp, J. T.
    Patra, K.
    Perez, J. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 176 - 176
  • [5] Three years of adalimumab (humira®) plus methotrexate therapy sustains radiographic inhibition of structural damage in patients with long-standing rheumatoid arthritis
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, GT
    Perez, JL
    Sasso, EH
    [J]. RHEUMATOLOGY, 2005, 44 : I71 - I71
  • [6] Safety of adalimumab (HUMIRA®) in global clinical trials of patients with early vs. long-standing rheumatoid arthritis (RA)
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 422 - +
  • [7] Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 2 years of treatment with adalimumab (Humira®) plus methotrexate
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, G
    Perez, JL
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 277 - 277
  • [8] Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA®) plus methotrexate.
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, GT
    Perez, JL
    Sasso, EH
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S189 - S189
  • [9] Subgroup analysis of radiographic progression in RA patients with moderate disease treated with adalimumab (Humira®)
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Spencer-Green, GT
    Szczerbak, NA
    Mydler, TT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 267 - 267
  • [10] Workplace impacts of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA)
    Birnbaum, Howard
    Pike, Crystal
    Kaufman, Rebecca
    Schiller, Matthew
    Shi, Lizheng
    Sun, Peter
    Ray, Saurabh
    Cifaldi, Mary
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S459 - S459
12345